Analysis of basic compounds in urine by on-line extraction-hplc-dad

Similar documents
1 Introduction 1 STA. High performance liquid chromatography (HPLC) Basic and acidic extract (plasma) Automated screening system, Bio-Rad (urine)

Opiates in Urine by SAMHSA GC/MS

Psychoactive Drugs Urine LC-MS/MS Analysis Kit User Manual

DRD Trends in Portugal: Updates From Forensic Toxicology Services

Yuhui Yang, An Trinh, Michael Ye, and Tom Henderson 595 North Harrison Road, Bellefonte, PA T HKB

Technical Procedure for Concentration Determination of Methamphetamine in Liquids via HPLC

Fractionation of Acidic, Basic, and Neutral Drugs from Plasma with an SPE Mixed Mode Strong Cation Exchange Polymeric Resin (Agilent SampliQ SCX)

Quantitative Analysis of EtG and EtS in Urine Using FASt ETG and LC-MS/MS

Abstract. Experimental Sample Preparation

Introduction to Pharmaceutical Chemical Analysis

METHADONE and EDDP in urine by GC-MS Code GC Method of Confirmation by GC-MS

Amphetamines, Phentermine, and Designer Stimulant Quantitation Using an Agilent 6430 LC/MS/MS

HANDBOOK OF DRUG ANALYSIS

Technical Procedure for Blood Cannabinoid Liquid-Liquid Extraction (BCLLE) for Analysis by LC-MS/MS

Rapid and Accurate Forensics Analysis using High Resolution All Ions MS/MS

Definitive EtG/EtS LC-MS/MS Analysis:

Quantitative Analysis of EtG and EtS in Urine Using FASt ETG and LC-MS/MS

Appendix II- Bioanalytical Method Development and Validation

Analysis of Cannabinoids and Amphetamines in Serum by RRLC/Triple Quadrupole Mass Spectrometry Using a Multimode Ion Source. Application.

ACETONE IN URINE BY UV CODE Z42010

High Performance Liquid Chromatography

Stability study of the designer drugs ``MDA, MDMA and MDEA'' in water, serum, whole blood, and urine under various storage temperatures

Semi-quantitative Determination of Concentrations in Systematic Toxicological Analysis by LC-QTOF-MS

Benzoylecgonine in Urine by SAMHSA GC/MS

7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.

NORBUPRENORPHINE (Buprenorphine s Metabolite ) BUPRENORPHINE in urine by GC/MS Code GC Method of Confirmation by GC-MS

VMA, HVA, 5-HIAA Urine LC-MS/MS Analysis Kit User Manual

USP Method Transfer and Routine Use Analysis of Irbesartan Tablets from HPLC to UPLC

RP-HPLC Method Development and Validation of Dapagliflozin in Bulk and Tablet formulation

HIPPURIC ACID, o-m-p-methylhippuric ACIDS and CREATININE IN URINE by UV CODE Z07510

trans,trans-muconic ACID IN URINE BY UV - CODE Z23010

25-OH VITAMIN D 3 AND 25-OH VITAMIN D 2 IN PLASMA BY UV / VIS FAST CODE Z19710

Chemical Analysis Problem

Quantitative analysis of small molecules in biological samples. Jeevan Prasain, Ph.D. Department of Pharmacology & Toxicology, UAB.

Zinc-Protoporphyrin/ Protoporphyrin HPLC Kit

High Pressure/Performance Liquid Chromatography (HPLC)

FORMALDEHYDE IN URINE by UV Code Z65010

Research Article METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF ELBASVIR AND GRAZOPREVIR BY RP-HPLC

Routine MS Detection for USP Chromatographic Methods

DEVELOPMENT AND VALIDATION OF NEW RP-HPLC METHOD FOR THE DETERMINATION OF AFLOQUALONE IN HUMAN PLASMA AND FORMULATION

DEVELOPMENT AND VALIDATION OF A HPLC METHOD FOR IN-VIVO STUDY OF DICLOFENAC POTASSIUM

Prepared By: R. W. Waggoner, Jr. Effective Date: August 18, 2008

RESOLUTION OENO 33/2004 DETERMINATION OF SHIKIMIC ACID IN WINE BY HPLC AND UV-DETECTION

Determination of Cannabinoids (THC) in Biological Samples

Fast methods for the determination of ibuprofen in drug products

Stability-indicating HPLC determination of tolterodine tartrate in pharmaceutical dosage form

Intercontinental journal of pharmaceutical Investigations and Research

STABILITY INDICATING METHOD OF RELATED IMPURITIES IN VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS

CHAPTER 1 Role of Bioanalytical Methods in Drug Discovery and Development

Introduction to E&Ls 1

Figure 1. Structures for Vitamin B2 and Vitamin B1.

Impact factor: 3.958/ICV: 4.10 ISSN:

Technical Procedure for Solid Phase Extraction of THC and THC-COOH for GC-MS Analysis

DEVELOPMENT OF HPLC METHOD FOR ANALYSIS OF NITRITE AND NITRATE IN VEGETABLE

Analytical Chemistry

Phenobarbital analysis in biological matrix (blood) by high performance liquid chromatography (HPLC)

Application Note. Author. Abstract. Pharmaceutical QA/QC. Siji Joseph Agilent Technologies, Inc. Bangalore, India

Overview. Introduction. NMR hyphenation modes HPLC-SPE-NMR. Advantages and limitations. Examples

Application Note. Pharmaceutical QA/QC. Author. Abstract. Siji Joseph Agilent Technologies, Inc. Bangalore, India

HIPPURIC ACID and o-m-p- METHYLHIPPURIC ACIDS IN URINE BY UV CODE Z06010

Maximizing Triple Quadrupole Mass Spectrometry Productivity with the Agilent StreamSelect LC/MS System

Journal of Analytical Toxicology Advance Access published April 24, 2012

Detection of 9-tetrahydrocannabinol ( 9-THC) in human urine by Solid Phase Extraction and HPLC.

Development of an in-house HPLC method for the analysis of ecstasy-laced beverages

Determination of Beta-Blockers in Urine Using Supercritical Fluid Chromatography and Mass Spectrometry

VALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION

Application Note. Gas Chromatography/Mass Spectrometry/Food Safety. Abstract. Authors

Method Development and Validation for the Estimation of Darunavir in Rat Plasma by RP-HPLC

Automatization for development of HPLC methods

Determination of underivatized aflatoxins B2, B1, G2, and G1 in ground hazelnuts by immunoaffinity solid-phase extraction with HPLC-FLD detection

FORENSIC TOXICOLOGY SCREENING APPLICATION SOLUTION

FORMIC ACID in URINE by GC/MS-headspace - Code GC74010

Modernizing the USP Monograph for Acetaminophen

Laboratory Guidelines

Effects of Aqueous Sample Content and Aqueous Co-Solvent Composition on UPC 2 Separation Performance

Agilent 1200 Infinity Series HDR DAD Impurity Analyzer System for the Quantification of Trace Level of Genotoxic Impurity

Journal of Pharmaceutical and Biomedical Analysis Letters. Analysis Letters

Reverse Phase High Performance Liquid Chromatography method for determination of Lercanidipine hydrochloride in bulk and tablet dosage form

Development and validation a RP-HPLC method: Application for the quantitative determination of quetiapine fumarate from marketed bulk tablets

Figure 1. Structures for Vitamin B2 and Vitamin B1.

Technical Procedure for ELISA Drug Screen Version 3 Toxicology Unit Effective Date: 02/15/2013. ELISA Drug Screen

Development and Validation of RP-HPLC Method for the Determination of Methamphetamine and Propranolol in Tablet Dosage Form

CHAPTER - 3 ANALYTICAL PROFILE. 3.1 Estimation of Drug in Pharmaceutical Formulation Estimation of Drugs

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

High-Resolution Sampling 2D-LC for Pharmaceutical Impurity Analysis

Toxicology Extraction Procedure for Base Drugs Using United Chemical Technologies Clean Screen Extraction Columns

Prep 150 LC System: Considerations for Analytical to Preparative Scaling

Evaluation of Ketone Containing Terpene Compounds using Evaporative Light Scattering Detection

Development and validation of RP-LC method for lisinopril dihydrate in bulk and its pharmaceutical formulations

Liquid storage: Holds the solvent which is going to act as the mobile phase. Pump: Pushes the solvent through to the column at high pressure.

Available online Research Article

DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

25-OH VITAMIN D 3 IN PLASMA BY UV FAST CODE Z19610

COMPLEX HEROIN COMPARISON INVESTIGATION

Uncontrolled Copy. SOP 109 Ethylene Glycol Screen by Gas Chromatography/Mass Spectrometry. Table of Contents. 1. Principle of Assay...

penta-hilic UHPLC COLUMNS

GUIDELINES ON THE USE OF MASS SPECTROMETRY (MS) FOR IDENTIFICATION, CONFIRMATION AND QUANTITATIVE DETERMINATION OF RESIDUES CAC/GL

Development and Validation of a HPLC Method for Determination of Anastrozole in Tablet Dosage Form

EVOLUTE WCX Columns for Solid Phase Extraction of Quaternary Amines and Strongly Basic Compounds from Aqueous Samples

The role of LC-MS in Toxicology

Transcription:

T + K (7) 74 (1): 64 Analysis of basic compounds in urine by on-line extraction-hplc-dad Lena Schönberg a,b, Thomas Grobosch a, Dagmar Lampe a and Charlotte Kloft b,c a Berliner Betrieb fuer Zentrale Gesundheitliche Aufgaben (BBGes), Institute of Clinical Toxicology Clinical Toxicology and Poison Control Centre, Oranienburgerstr. 285, D-13437 Berlin, Germany b Department of Clinical Pharmacy, Institute of Pharmacy, Freie Universitaet Berlin, Kelchstr. 31, D-12169 Berlin, Germany c Department of Clinical Pharmacy, Faculty of Pharmacy, Martin-Luther-Universitaet Halle-Wittenberg, Wolfgang-Langenbeck-Strasse 4, D-612 Halle-Wittenberg, Germany Abstract An automated, qualitative screening HPLC method for the identification of basic compounds in urine has been established. A 1-ml volume of urine was extracted by on-line extraction and separated on two coupled strong cation-exchange columns under isocratic conditions. The use of the photodiode-array detector (DAD, = 19-37 nm) gave access to a library of > 26 toxicologically relevant compounds. The validated method is reliable, simple and in addition successfully proven with the analysis of real biological specimen for the routine use. 1. Introduction Systematic toxicological analysis (STA) based on GC, HPLC and immunological methods is usually performed in plasma/serum and urine. However, some compounds such as psilocin, scopolamine and morphine with very short half-lives in blood, are difficult to detect with common STA screening methods and require specialised analytical methods. The Remedi TM - HS (Bio-Rad, Munich, Germany) presents such a specialised system for the analysis of basic compounds (e.g. alkaloids). However, it will be taken out of service at the end of 8. The aim of this study was to develop a chromatographic screening method for toxicological analysis in urine with main focus on basic compounds, taking advantage of the larger time window of detection in urine compared to blood. Furthermore, as urine presents the matrix of choice for drugs of abuse (DOA) analysis, it was proved if the method is suitable for this field of application. A HPLC-system with a DAD was chosen to access a commercially available spectra library with >26 spectra [1] and to allow the identification of toxicologically relevant metabolites by comparing their spectra to those of the parent compound. In addition, all chromatographic data of investigated compounds including metabolites that are not available as drug standards were stored in an additional library for spectra and relative retention time comparison (method specific library). To hold sample pre-treatment and costs to a minimum, the developed method was characterised by fully automated on-line extraction and common HPLC equipment (columns, solvents). With the developed method specialised methods such as the Remedi TM -HS (analysis of alkaloids, drugs of abuse analysis) should be replaced. The utility of the developed method for STA and DOA is discussed in the following and illustrated with example chromatograms of both, the developed system and the Remedi TM -HS. 2. Material and methods Urine samples Urine samples were sent to our laboratory from hospital emergency rooms, psychiatric units and substance abuse clinics for analysis. The samples were delivered in monovettes and stored at 5-8 C until they were analysed.

T + K (7) 74 (1): 65 Sample preparation The urine samples were centrifuged for 5 min at 15 x g, 1. ml of each sample was transferred to a 2.-mL polypropylene cup, diluted with µl internal standard solution, vortexed and centrifuged again for 5 min at 15 x g. The samples were placed into the auto sampler. The injection volume was 1. ml. Extraction and analytical procedure Following sample preparation, the sample was applied with.1 M phosphate buffer ph 6 to the on-line extraction column (StrataX-CW TM ). On the weak cation-exchange material of the on-line extraction column, basic target analytes were retained and the urine matrix was washed into the waste. After two subsequent wash steps in the forward (acetonitrile/water) and back flush mode (water), respectively. The analytes were eluted to the analytical columns (2 x LunaSCX (1 x 4.6 mm)) with mobile phase (31.5% ACN/H 2 O (9/1, v/v) and 68.5%.5 M phosphate buffer ph 2.3). Separation was carried out under isocratic conditions at a flow rate of 1.2 ml/min. The time required for the analytical procedure including on-line extraction was 41 min. Validation The method was validated using an exemplary performance control test consisting of six different analytes which represented the following groups of interest: alkaloids (scopolamine), amphetamine derivatives (methylenedioxyamphetamine (MDA)) opiates (codeine and morphine), the methadone metabolite 2-ethyliden-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP) and the internal standard neostigmine bromide (). Recovery of the performance control test analytes was > 73-97%. The results for the intraassay precision ranged from.4-7.2% (n = 6), inter-assay precision was < 8% and linearity for the analytes was obtained from.1-15. µg/ml (R 2 >.995) for codeine, EDDP and morphine,.1-5. µg/ml for MDA (R 2 =.993) and.25-15. µg/ml for scopolamine and (R 2 >.993), respectively. The method showed sufficient selectivity/specificity and the lower limit of detection was.1 µg/ml (S/N >3) and.25 µg/ml (S/N >3) for scopolamine. All stock solutions showed stability over a time period of 28 days. The detailed method and validation data has been published elsewhere [2]. 3. Results To prove the utility of the developed method for toxicological screening of urine, authentically clinical samples, were analysed. The results were compared to results achieved by the Remedi TM -HS-system [3]. The evaluation of the data of 45 samples demonstrated, that the developed analytical database represents a reliable method for the identification of basic substances. A detailed report will be given subsequently [4]. In the following figures example chromatograms of two intoxication cases (Fig. 1 and 2) and two drugs of abuse confirmation cases (DOA, Fig. 3 and 4) are shown, which were analysed with the developed system (left) and the Remedi TM -HS (right). As can be seen from the Figures 1-4, both compared methods showed the same analysis results and thus can be used for the same fields of application. In cases of STA, the HPLC- UV method should be used as a complementary method to other methods within the rational chemical-analytical approach of general unknown screening in order to identify as many xenobiotics as possible. According to N. Sadeg et al. who described a 12 months` experience of toxicological screening with the Remedi TM -HS in a general hospital in France [6], it can be stated for the developed method as well, that it presents a valuable tool for additional urine screening within STA.

T + K (7) 74 (1): 66 4 3 Psilocin 2 1 Psilocin 2 1 1 2 3 min Fig. 1. STA: Psilocin intoxication, female patient, date of birth 1998, creatinine value.98 g/l. Psilocin analysis was performed after glucuronide hydrolysis with ß-glucuronidase from E. coli (14 units/mg, Roche, Mannheim) for 1.5 h at 45 C 3 2 Amitriptyline-Metabolite Amitriptyline-Metabolite Nortriptyline 1 2 1 1 2 3 min Fig. 2. STA: Amitriptyline intoxication, female, date of birth 1977, creatinine value.22 g/l 3 2 1 6-Acetylmorphine Normorphine Morphine Codeine 1 2 3 min Morphine 1 6-Acetyl- Codeine morphine 2 Fig. 3. DOA: Confirmation screening, male, date of birth not given, creatinine.15 g/l.

T + K (7) 74 (1): 67 3 2 1 Amphetamine MDA Amphetamine MDA MDMA MDMA Metamphetamine Metamphetamine 2 1 2 3 min Fig. 4. DOA: Confirmation screening, person unknown, creatinine.66 g/l As can be seen from the Figures 1-4, both compared methods showed the same analysis results and thus can be used for the same fields of application. In cases of STA, the HPLC- UV method should be used as a complementary method to other methods within the rational chemical-analytical approach of general unknown screening in order to identify as many xenobiotics as possible. According to N. Sadeg et al. who described a 12 months` experience of toxicological screening with the Remedi TM -HS in a general hospital in France [6], it can be stated for the developed method as well, that it presents a valuable tool for additional urine screening within STA. The shorter analysis time of the Remedi TM -HS (approx. 2 min versus 41 min (developed method)) presents an advantage for fast diagnosis in intoxication cases. However, both methods should be ideally run as part of a complex analysis strategy within STA in acute intoxication cases which takes about 1-2 h. Thus, 41 min for analysis is still acceptable and means that measurement of approximately 32 samples per 24 h is possible. In cases of DOA, immunological pre-screening should be performed. If the immunoassay result cannot be verified by the HPLC-UV method, a more sensitive method must be considered. Therefore GC-MS remains the gold standard for DOA confirmation screening in urine [5]. With the developed method a broad screening of basic analytes from urine was possible for the analysis of acute intoxications as well as for confirming the intake of drugs of abuse within the given limit of detection. The method is simple, automated and does not require special sample pre-treatment such as derivatisation. The retention and relative retention times in addition to the characteristic spectra allowed individual compounds to be identified from the complex components contained in human urine. The function of the analytical system concerning extraction, recovery and retention time was monitored by a validated performance control sample. 4. Conclusion An automated method for the qualitative determination of basic drugs from urine was established and validated. The use of on-line extraction permitted the direct injection of urine samples after dilution and centrifugation, which held sample preparation to a minimum and replaced tedious and time-consuming purification steps. The elution under isocratic conditions as well as the use of common HPLC solvents and equipment simplified the method and the method set up. The analysis of authentically toxicological samples proved the utility for toxicological applications, as was illustrated by four example chromatograms and will be reported more detailed subsequently [4]. The validation data met the criteria set in international guidelines for bioanalytical methods [7] and confirmed the reliability of the method. Time required for the complete analysis was 41 min.

T + K (7) 74 (1): 68 In conclusion, the developed on-line extraction-hplc-dad method allowed simple and reliable determination of basic drugs in urine and is suitable for the routine use as initial results of authentically sample analyses showed. References [1] F. Pragst, M. Herzler, S. Herre, B.-T. Erxleben, M. Rothe, UV spectra of toxic compounds. Dr. Dieter Helm, Heppenheim, 1. [2] L. Schönberg, T. Grobosch, D. Lampe, C. Kloft, New screening method for basic compounds in urine by on-line extraction high-performance liquid chromatography with photodiode-array detection, J. Chromatogr. A, 1134: 177-185 (6). [3] S. R. Binder, M. Regalia, M. Biaggi-McEachern, M. Mazhar, Automated liquid chromatographic analysis of drugs in urine by on-line sample cleanup and isocratic multicolumn separation, J. Chromatogr., 472: 325-341 (1989). [4] L. Schönberg, T. Grobosch, D. Lampe, C. Kloft, Toxicological Screening in Urine: Comparison of two Automated HPLC Screening Systems (Toxicological Identification System (TOX.I.S.*) versus REMEDI TM -HS), J. Anal. Toxicol., submitted. [5] H.H. Maurer, Position of chromatic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping control, Clin. Chem. Lab. Med., 42 (11): 131-1324 (4). [6] N. Sadeg, G. Francois, B. Petit, H. Dutertre-Catella, M. Dumontet, Automated liquid-chromatographic analyzer used for toxicology screening in a general hospital: 12 months` experience, Clin.Chem. 43: 3, 498-4, 1997. [7] U.S. Food and Drug Administration (FDA), http://www.fda.gov/cder/guidance/4252fnl.pdf